Nifty
Sensex
:
:
10682.20
35457.16
65.50 (0.62%)
196.62 (0.56%)

Pharmaceuticals & Drugs

Rating :
71/99

BSE: 532523 | NSE: BIOCON

624.95
-1.20 (-0.19%)
16-Nov-2018 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  630.00
  •  633.95
  •  622.50
  •  626.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  956390
  •  5976.96
  •  718.00
  •  379.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 37,578.00
  • 53.94
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 38,519.20
  • 0.16%
  • 6.59

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 0.00%
  • 10.73%
  • FII
  • DII
  • Others
  • 1.15%
  • 3.59%
  • 23.86%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.87
  • 7.46
  • 7.20

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.87
  • 3.83
  • 1.55

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.10
  • -3.23
  • -12.76

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.84
  • 21.83
  • 31.57

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.53
  • 4.06
  • 4.90

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.45
  • 18.87
  • 23.50

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
1,321.00
968.60
36.38%
1,123.80
933.70
20.36%
1,169.50
931.10
25.60%
1,057.90
1,044.40
1.29%
Expenses
981.40
786.30
24.81%
886.00
741.60
19.47%
936.50
743.60
25.94%
836.20
768.30
8.84%
EBITDA
339.60
182.30
86.29%
237.80
192.10
23.79%
233.00
187.50
24.27%
221.70
276.10
-19.70%
EBIDTM
25.71%
18.82%
21.16%
20.57%
19.92%
20.14%
20.96%
26.44%
Other Income
54.40
50.80
7.09%
68.80
54.00
27.41%
67.50
43.20
56.25%
33.90
47.40
-28.48%
Interest
18.80
13.80
36.23%
17.60
16.10
9.32%
16.90
5.00
238.00%
14.70
8.80
67.05%
Depreciation
112.20
93.60
19.87%
99.10
98.80
0.30%
95.30
72.50
31.45%
97.40
70.30
38.55%
PBT
451.80
125.70
259.43%
189.90
131.20
44.74%
188.30
153.20
22.91%
143.50
244.40
-41.28%
Tax
73.20
42.50
72.24%
52.10
37.60
38.56%
40.70
10.30
295.15%
36.10
54.40
-33.64%
PAT
378.60
83.20
355.05%
137.80
93.60
47.22%
147.60
142.90
3.29%
107.40
190.00
-43.47%
PATM
28.66%
8.59%
12.26%
10.02%
12.62%
15.35%
10.15%
18.19%
EPS
5.91
1.15
413.91%
2.00
1.36
47.06%
2.17
2.13
1.88%
1.53
2.86
-46.50%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
4,672.20
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
1,608.67
Net Sales Growth
20.49%
5.97%
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
-23.73%
47.19%
 
Cost Of Goods Sold
1,779.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
838.42
Gross Profit
2,892.60
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
770.25
GP Margin
61.91%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
47.88%
Total Expenditure
3,640.10
3,294.30
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
1,285.31
Power & Fuel Cost
-
189.00
156.40
184.70
176.70
162.40
142.60
97.20
82.00
67.63
69.33
% Of Sales
-
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
4.31%
Employee Cost
-
931.10
747.00
610.10
533.40
466.30
389.40
307.60
238.80
242.76
179.18
% Of Sales
-
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
11.14%
Manufacturing Exp.
-
335.70
391.50
320.90
81.20
62.90
95.20
113.20
81.60
68.63
66.01
% Of Sales
-
8.14%
10.06%
9.59%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
4.10%
General & Admin Exp.
-
56.80
21.70
42.60
165.70
131.80
122.20
93.20
82.40
79.09
56.15
% Of Sales
-
1.38%
0.56%
1.27%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
3.49%
Selling & Distn. Exp.
-
98.20
107.40
100.80
108.70
118.90
99.60
89.40
62.40
56.49
47.67
% Of Sales
-
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
2.96%
Miscellaneous Exp.
-
47.40
41.00
30.10
72.70
61.80
52.90
256.70
940.80
44.19
47.67
% Of Sales
-
1.15%
1.05%
0.90%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
1.77%
EBITDA
1,032.10
829.10
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
471.49
323.36
EBITDA Margin
22.09%
20.11%
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
20.10%
Other Income
224.60
206.20
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
37.02
64.55
Interest
68.00
61.50
26.00
29.30
8.90
1.70
8.10
12.40
24.30
16.89
17.66
Depreciation
404.00
385.10
277.20
248.70
221.00
203.60
179.30
175.80
156.70
140.14
110.25
PBT
973.50
588.70
833.40
569.00
519.00
537.70
408.30
398.40
447.10
351.47
260.00
Tax
202.10
156.90
161.60
142.20
95.70
106.90
97.50
55.90
72.10
48.67
11.84
Tax Rate
20.76%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
10.50%
PAT
771.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
293.25
93.84
PAT before Minority Interest
685.80
431.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
302.81
100.97
Minority Interest
-85.60
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
-7.13
PAT Margin
16.51%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
5.83%
PAT Growth
51.34%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
25.32%
212.50%
 
Unadjusted EPS
11.61
6.31
10.39
28.04
24.87
21.09
25.99
17.27
18.79
15.08
4.83

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
1,510.74
Share Capital
300.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
4,812.30
4,670.20
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
1,369.32
Non-Current Liabilities
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
564.44
570.54
Secured Loans
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
331.50
395.73
Unsecured Loans
2.80
3.90
11.40
11.40
25.80
40.00
60.50
65.80
182.11
128.18
Long Term Provisions
49.30
36.00
29.90
15.00
7.80
4.00
0.00
1.00
0.00
0.00
Current Liabilities
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
438.50
Trade Payables
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
296.50
230.86
208.55
Other Current Liabilities
870.10
698.20
527.10
706.20
612.30
313.10
269.20
375.90
260.05
148.42
Short Term Borrowings
130.30
97.20
394.90
261.00
243.50
84.80
187.30
247.40
0.00
0.00
Short Term Provisions
135.60
143.20
133.90
158.20
176.60
246.50
211.50
140.80
90.83
81.53
Total Liabilities
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
Net Block
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
1,211.56
Gross Block
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
1,581.70
Accumulated Depreciation
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
499.20
370.14
Non Current Assets
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
1,422.68
Capital Work in Progress
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
172.02
Non Current Investment
63.80
188.80
26.80
0.00
64.50
64.50
64.20
60.90
47.16
39.10
Long Term Loans & Adv.
437.20
319.70
350.10
336.90
252.00
241.60
181.00
140.20
0.00
0.00
Other Non Current Assets
144.40
176.20
51.00
169.60
64.50
47.20
32.30
0.00
0.00
0.00
Current Assets
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
1,121.87
Current Investments
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
383.42
328.52
Inventories
722.50
635.30
542.40
452.70
376.60
398.40
378.30
413.70
371.64
319.18
Sundry Debtors
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
495.80
446.13
366.68
Cash & Bank
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
139.93
11.81
Other Current Assets
428.00
395.80
73.60
95.80
157.60
136.90
114.30
56.70
136.10
95.67
Short Term Loans & Adv.
54.70
24.10
227.10
75.80
81.80
81.40
37.10
20.20
120.28
95.05
Net Current Assets
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
683.37
Total Assets
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
662.10
640.00
526.40
210.70
560.70
471.20
564.10
798.50
443.81
95.10
PBT
610.00
849.70
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
104.36
Adjustment
355.70
204.40
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
135.89
Changes in Working Capital
-106.50
-211.10
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
-128.21
Cash after chg. in Working capital
859.20
843.00
773.20
344.10
709.40
565.20
638.00
879.80
476.60
112.04
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-197.10
-203.00
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
-16.94
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-684.00
-498.50
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
-232.19
Net Fixed Assets
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
-84.56
Net Investments
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
130.57
Others
-195.40
-203.30
2,951.00
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
-278.20
Cash from Financing Activity
-239.70
-177.50
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
136.93
Net Cash Inflow / Outflow
-261.60
-36.00
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
-0.16
Opening Cash & Equivalents
710.20
757.50
462.60
557.00
474.00
369.00
359.00
139.90
11.81
9.62
Closing Cash & Equivalent
449.00
710.20
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10
11.81

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
85.19
79.49
67.22
53.86
48.42
43.18
36.31
32.49
28.25
24.47
ROA
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
4.37%
ROE
8.74%
15.26%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
6.93%
ROCE
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
6.92%
Fixed Asset Turnover
0.73
0.89
1.05
1.09
1.12
1.11
1.06
0.97
1.42
1.19
Receivable days
86.05
74.35
80.16
80.09
69.48
72.22
84.37
93.20
60.98
69.27
Inventory Days
60.00
54.81
53.71
48.47
48.54
56.01
67.67
77.71
51.83
55.14
Payable days
87.96
78.68
68.27
58.15
55.73
65.24
70.25
70.62
41.52
51.80
Cash Conversion Cycle
58.09
50.48
65.60
70.42
62.29
62.99
81.79
100.29
71.30
72.61
Total Debt/Equity
0.44
0.48
0.61
0.35
0.30
0.10
0.12
0.17
0.30
0.36
Interest Cover
10.57
33.05
25.90
71.12
317.29
76.33
33.13
19.40
21.81
7.39

News Update:


  • USFDA conducts inspection at Biocon’s Bengaluru facility
    12th Nov 2018, 09:18 AM

    The audit concluded without any observations and no Form 483 was issued

    Read More
  • Biocon features in top global pharma & biotech employers list 2018
    30th Oct 2018, 14:23 PM

    Biocon's position has moved up two ranks from No. 9 last year

    Read More
  • Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri
    30th Oct 2018, 09:11 AM

    The positive CHMP opinion is based on data submitted as part of the Marketing Authorization Application

    Read More
  • Biocon reports over 5-fold jump in Q2 consolidated net profit
    26th Oct 2018, 11:27 AM

    Total consolidated income of the company increased by 34.92% at Rs 1,375.40 crore for Q2FY19

    Read More
  • Biocon reports more than double revenue from Biologics in Q2FY19
    26th Oct 2018, 10:48 AM

    The growth was driven by the commercial launch of biosimilar Pegfilgrastim in the US and strong sales of Insulins as well as biosimilar MAbs in key emerging markets

    Read More
  • Biocon - Quarterly Results
    25th Oct 2018, 18:09 PM

    Read More
  • Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri
    20th Oct 2018, 09:17 AM

    The positive CHMP opinion is based on data submitted as part of the Marketing Authorization Application

    Read More
  • USFDA completes cGMP inspection of Biocon’s Bangalore facility
    24th Sep 2018, 10:07 AM

    The successful audit of this site reflects the company’s strong commitment to cGMP compliance

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.